INTRODUCTION
============

Adhesion complexes are highly dynamic structures involved in the extension of a cell membrane for the purposes of locomotion. Movement of such cells involves polymerization of actin filaments and subsequent attachment to the extracellular matrix ([@B12]; [@B48]). Through studies on cultured murine fibroblasts, paxillin has been shown to be one of the key proteins required for proper maintenance and/or turnover of focal adhesion complexes ([@B19]). Much of the work on paxillin has focused on its role in adhesion structures in cultured cells, but paxillin is also highly expressed in skeletal muscle, cardiac muscle, and smooth muscle ([@B55]). Because relatively little is known about the function of paxillin in muscle, the study of this protein in model organisms may help to elucidate its in vivo function (reviewed in [@B11]; [@B15]). *Caenorhabditis elegans* is an appropriate organism with which to study the role of paxillin in muscle because nematode body wall muscles contain actin attachment structures analogous to Z-discs in vertebrate muscle called dense bodies, which also bear striking resemblance to adhesion complexes in terms of protein composition and function ([@B28]).

Paxillin is a well-conserved protein found in many organisms, including humans ([@B54]), zebrafish ([@B14])**,** and fruitfly ([@B59]). Human paxillin is a 591--amino acid protein with five LD motifs in its N-terminal region and four *lin-11*, *isl-1*, *mec-3* (LIM) domains in its C-terminal half ([@B54]; [@B56]). LD motifs are short stretches of amino acids with a consensus sequence of LDXLLXXL ([@B10]), although variations from this sequence are possible across species and even within the third LD motif (reviewed in [@B52]). The LD motifs are responsible for mediating many of the direct interactions that paxillin has with other proteins in focal adhesion complexes ([@B10]; [@B11]). LIM domains are tandem zinc fingers that are responsible for mediating interactions with other proteins ([@B50]), and the four LIM domains in paxillin have been shown to be sufficient for its localization to adhesion complexes ([@B10]).

Paxillin is found in another type of adhesion complex called the podosome ([@B7]). Similar to focal adhesion structures, podosomes are dynamic structures and include many of the same proteins but have a different structural arrangement of these proteins. Whereas focal adhesions comprise a complex of proteins extending inward from the cell membrane and anchoring actin filaments, podosomes have a core of F-actin ([@B34]), which has focal adhesion components such as paxillin, vinculin, and talin organized around the actin core in a ring-shaped formation ([@B7]). Recently, podosome-like structures in cultured myotubes have been shown to play a role at neuromuscular junctions by guiding and remodeling the postsynaptic membrane as it matures ([@B43]). Podosomes are found in a variety of cell types, including smooth muscle cells ([@B20]; [@B27]) and migrating cells ([@B31]), and, like adhesion complexes, are able to play a role in cell movement ([@B31]).

Previously, little work has been done on the structural organization of actin attachment sites in *C. elegans* pharyngeal muscle. Much of the work directed on muscle in the worm has focused on the body wall muscle. Whereas body wall muscle is comprised of cells with multiple sarcomeres in register (reviewed in [@B39]; [@B40]), pharyngeal muscles contain a series of single sarcomeres that traverse the diameter of the cell ([@B2]). Pharyngeal muscle in the worm has been proposed as a possible model for cardiac muscle, albeit with limitations ([@B33]), whereas body wall muscle is generally used as a model for mammalian skeletal muscle, again with limitations ([@B40]). As previously mentioned, dense bodies in body wall muscle are actin attachment sites functionally similar to Z-discs in mammalian muscle ([@B40]), and transmission electron microscope (TEM) images of pharyngeal muscle cells also show similar electron-dense structures at the ends of actin filaments ([@B2]). Whereas green fluorescent protein (GFP)--tagged body wall muscle proteins that localize to dense bodies show a punctate pattern indicating localization throughout the sarcolemmal plane of the dense body, to date the specific organization of muscle proteins within the pharyngeal muscle dense bodies has not been established.

We have found that a single paxillin homologue is present in the genome of *C. elegans* and is expressed in body wall and pharyngeal muscle cells at sites of actin attachment. Animals homozygous for a *pxl-1* deletion have paralyzed pharyngeal muscle and arrest and die as first-stage larvae. A GFP translational fusion for *pxl-1* expressed exclusively in pharyngeal muscle and marginal cells restores pharyngeal muscle function in *pxl-1* mutants, indicating that although *pxl-1* is expressed in body wall muscle and pharyngeal muscle, its essential role is within the pharynx.

RESULTS
=======

*pxl-1* encodes three splice variants of paxillin
-------------------------------------------------

The gene C28H8.6 (*pxl-1)*, found near the center of chromosome III, encodes three splice variants of a paxillin-like gene ([Figure 1A](#F1){ref-type="fig"}). The largest of these splice variants encodes a 413--amino acid protein with sequence similarity to paxillin in other species, including humans. Human paxillin is a 557--amino acid protein containing an LD motif rich region in its N-terminal half and four LIM domains in its C-terminal half. ([@B10]). Splice variant a of *C. elegans* paxillin codes for a protein product with LD motifs in its amino half, albeit truncated as compared with its human counterpart, and four LIM domains in its C-terminal half ([Figure 1B](#F1){ref-type="fig"}). An alignment of the two proteins using ClustalW2 ([@B13]) reveals significant similarity between *C. elegans* and human paxillin throughout the protein, with some gaps in the *C. elegans* portion of the alignment in the LD motif region due to its shorter sequence length ([Figure 2](#F2){ref-type="fig"}). In terms of the LD motifs, PXL-1 appears to share LD motifs 1, 3, and 5 but not 2 and 4 ([Figure 1C](#F1){ref-type="fig"}). This overall similarity, and the fact that there are no other predicted nematode proteins with this combination of domains, supports the possibility that PXL-1 may be the nematode orthologue of human paxillin.

![*C. elegans* paxillin (*pxl-1*) gene and protein models. The *pxl-1* gene in *C. elegans* has three alternatively spliced isoforms (A), which are all affected by the deletion allele *ok1483.* Exons are in black, with the UTR in white. Conservation of three of the five LD motifs found in the N-terminal half of paxillin in *H. sapiens* (PXN) is found in the a isoform of PXL-1, two of the 5 LD motifs in isoform c, and only one LD motif in isoform b. (B). Sequence homology between the LD motifs can be seen in C. Bar, 500 base pairs.](2551fig1){#F1}

![Comparison of PXL-1 protein sequence with paxillin (*H. sapiens*). PXL-1a aligns strongly with human, fly, and frog paxillin, especially in the LIM domain C-terminal half of the protein (A) using ClustalW2 software. Within the N-terminal half of PXL-1, homology is seen between species, with PXL-1 containing three of the five LD motifs found in the each of the compared proteins (B). Amino acid alignments were marked using ClustalW2 conventions ([@B29]): asterisks (\*), identical amino acids; colons (:), conserved substitutions; periods (.), semiconserved substitutions. Bars below the LIM domains mark their boundaries.](2551fig2){#F2}

*pxl-1* mutant animals die as young larvae
------------------------------------------

The C*. elegans* Gene Knockout Consortium provided the strain VC1012, which carries a 943-bp deletion within the coding sequence of C28H8.6 ([Figure 1A](#F1){ref-type="fig"}). When homozygous for the mutant allele *ok1483*, animals arrest at the first larval stage of development (L1), which is ∼0.2 mm in length, and die. Whereas a wild-type worm grows to ∼1 mm in length at the adult stage after 3 d and begins to lay eggs, *pxl-1* mutants remain at ∼0.2 mm in length. On close examination of the pharynx in mutant animals, a lack of pumping is clearly noticeable. The pharynx structure appears to be normal, and we detect no visible attachment defects ([Figure 3B](#F3){ref-type="fig"}) like those seen in the α-integrin mutant *ina-1* ([@B6]), but the pharyngeal muscles do not contract. The internal pharyngeal muscle structure can be observed by using polarized light microscopy ([@B3]), and on closer examination, the birefringence of myofilaments in animals lacking PXL-1 is reduced throughout most of the pharyngeal muscle ([Figure 3D](#F3){ref-type="fig"}). The reduced birefringence of pharyngeal myofilaments that we observe is very similar to that observed in an actin mutant ([@B3]; [Figure 5C--5D](#F5){ref-type="fig"}). This lack of organized myofilament structure and thus pharyngeal pumping in *pxl-1(ok1483)* homozygotes means the animals cannot feed, so we presume that the animals die of starvation as L1 larvae. The interfering RNA (RNAi) phenotype of worms fed dsRNA for *pxl-1* is similar in appearance to *ok1483* lethal homozygotes. Whereas a balanced lethal animal contributes maternal transcripts due to its heterozygous genotype, RNAi knocks down the gene product for *pxl-1* in the treated adult animals, and thus a maternal contribution of *pxl-1* cannot occur in its progeny. The lack of a stronger phenotype using RNAi indicates that there is no maternal contribution of *pxl-1* that is critical to the developing embryo.

![Phenotype of homozygous *pxl-1 (ok1483)* mutant animals and subcellular localization of PXL-1::GFP translational fusion products. The pharynx of *pxl-1* mutants does not pump, but the physical structure of the pharynx in wild-type worms (A) appears similar to the structure in *pxl-1* mutant animals (B). Within the pharyngeal muscle, polarized light microscopy was used to look at the myofilament structure. In worms with *pxl-1* expression restored in the pharynx, myofilaments extend across the pharyngeal muscle cells, indicated by arrows highlighting the birefringence of the myofilaments (C). Animals not expressing *pxl-1::GFP* arrest at the L1 stage of development and have a lack of myofilament birefringence in pharyngeal muscle (D). *pxl-1a(cDNA)::GFP* is expressed strongly in body wall muscle (E) and pharyngeal muscle under control of its endogenous promoter. PXL-1a(cDNA)::GFP is localized to dense bodies (arrows) and adhesion plaques (star) and weakly to M-lines (not shown). A GFP fusion product containing only the four LIM domains of PXL-1 fused to GFP also localizes to dense bodies (arrows) and adhesion plaques (star) and weakly to M-lines (arrowhead) (F). *pxl-1a/c::GFP* under control of a minimal promoter lacking body wall muscle promoter elements is expressed strongly in the pharyngeal muscle and weakly in body wall muscle (arrow), solely at the anterior tip of the animal (G). Within pharyngeal muscle, PXL-1a/c::GFP and PXL-1a(CDNA)::GFP (not shown but identical to PXL-1a/c::GFP) is localized to ring-shaped structures near the muscle cell membrane (H). Bars: A--D, 10 μm; E--F, 2 μm.](2551fig3){#F3}

Isoform diversity leads to differential subcellular location and tissue expression of paxillin
----------------------------------------------------------------------------------------------

We first rescued the *pxl-1* mutant phenotype with a GFP translational fusion containing ∼2.4 kb of upstream promoter sequence, the full *pxl-1* gene, and GFP sequence tagged to the terminal exon of *pxl-1* in the expression vector pPD95.75 (provided by Andrew Fire, Stanford University, Stanford, CA). Because the 3′ exon for the b isoform is downstream of the terminal exon for *pxl-1a* and *pxl-*1c, non--GFP-tagged PXL-1a and PXL-1c are produced from the extrachromosomal array, along with GFP-tagged PXL-1b. This construct fully rescued the first larval stage arrest phenotype. In addition, we noted that PXL-1b::GFP is diffusely expressed in the pharyngeal epithelial cells and weakly so in pharyngeal muscles one and three.

Isoform a is most similar to human paxillin. We used a full-length cDNA for *pxl-1a* to create a GFP-tagged injectable marker, under the control of a ∼2.5-kb endogenous promoter. We found the a isoform of paxillin in all 95 body wall muscle cells in an adult animal, as well as in the pharyngeal muscle cells. Strong localization of PXL-1a(cDNA)::GFP is seen in adult body wall muscle at dense bodies, as well as adhesion plaques between adjacent muscle cells ([Figure 3E](#F3){ref-type="fig"}). Weak GFP localization also can be observed at the M-line (not shown). In the pharynx, expression of PXL-1a(cDNA)::GFP can be seen in all muscle cells, localized to both the luminal and cuticular membranes. PXL-1a(cDNA)::GFP is localized in small punctae, as well in ring-like structures near muscle cell membranes (identical to [Figure 3F](#F3){ref-type="fig"}). We were unable to design a c isoform--specific GFP reporter because it shares its 3′-terminal exon with the a isoform, so we do not know whether the distribution of this isoform overlaps or mimics the a and/or b isoforms.

To reinforce our conclusions on paxillin subcellular localization within muscle, a polyclonal antibody was raised against the full-length PXL-1a protein. This antiserum is able to bind to PXL-1 in both nematode lysate and yeast lysate expressing hemagglutinin (HA)-tagged PXL-1 via Western blot ([Figure 4D](#F4){ref-type="fig"}). The PXL-1 antiserum was also used to verify the localization pattern seen with our GFP constructs. Within adult body wall muscle the PXL-1a antibody localizes to dense bodies and adhesion plaques and very weakly to M-lines ([Figure 4C](#F4){ref-type="fig"}), colocalizing with PAT-3/β-integrin. Within the pharynx, there is staining within the muscle cells, but the staining is somewhat fuzzy and punctate (unpublished data).

![Confirmation of protein interactions and immunostaining with a PXL-1 antibody (A). Screening by the yeast two-hybrid method of a collection of 30 known components of dense bodies and M-lines revealed that the six indicated proteins interact with PXL-1. By domain mapping, the LD motif region is sufficient for interaction with DEB-1 (vinculin) and LIM-8, and the LIM domain region is sufficient for interaction with UNC-95 and UIG-1 (a Cdc42 GEF). UNC-96 and HUM-6 are also able to bind to PXL-1. (B) These interactions, except that with HUM-6, were verified using purified proteins. Yeast-expressed HA-tagged PXL-1 was precipitated with anti-HA beads, washed, incubated with bacterially expressed MBP of the indicated MBP fusion proteins, and washed, and the eluted proteins were separated on a gel, blotted, and reacted with either anti-MBP or anti-HA. All tested proteins except UNC-96 showed conclusive results, with a faint band observed in 5B when reacted with anti-MBP. A paxillin (PXL-1) polyclonal rabbit antibody was produced to detect PXL-1 in *C. elegans* as well as in yeast expressing HA-PXL-1. PAT-3/β-integrin (GFP; Ci) is a major component of dense bodies, M-lines, and attachment plaques, and the PXL-1 antibody (Cii) clearly colocalizes with PAT-3/β-integrin in dense bodies and adhesion plaques (Ciii). The PXL-1 antibody also stains M-lines, but very weakly (not shown). Paxillin from the nematode lysate displays a slower mobility than that of nematode paxillin expressed in yeast (see *Discussion*) (D). Bar, 2 μm.](2551fig4){#F4}

Pharyngeal muscle *pxl-1* rescue
--------------------------------

It was not clear why *pxl-1* null animals die, although we suspected that it was a result of starvation, not a problem with the body wall muscle. To test this possibility, we designed a *pxl-1* construct with expression only in the pharynx. Using the *C. elegans* muscle *cis*-regulatory module locator ([@B61]) showed that the *pxl-1* promoter has multiple body wall muscle--specific expression motifs between 250 base pairs upstream of the transcriptional start site and 3 kb upstream. We cloned the genomic region of *pxl-1* covering the a and c isoforms along with the immediate 5′ ∼150 base pairs of the endogenous promoter in frame with sequence encoding GFP. The translational fusion construct produces GFP-tagged PXL-1a and PXL-1c, but because the terminal exon for *pxl-1b* is downstream of the terminal exon for *pxl-1a/c*, PXL-1b is not produced, at least not as a full-length protein (see [Figure 1](#F1){ref-type="fig"}, A and B, for clarification). The L1 arrest phenotype was fully rescued using this construct. The tissue expression using the minimal promoter is almost solely within the pharyngeal muscle cells. Only a few body wall muscle cells around the anterior tip of the worm display a faint GFP signal, but otherwise expression from this PXL1a/c::GFP construct is pharyngeal specific ([Figure 3G](#F3){ref-type="fig"}). Progeny carrying this extrachromosomal array display wild-type movement, and the body wall muscle structure appears wild type using both polarized light microscopy ([Figure 5, A and B](#F5){ref-type="fig"}) and transmission electron microscopy ([Figure 5, E and F](#F5){ref-type="fig"}). Within the pharynx, we again observe that paxillin is associated with ring-like structures similar to those previously described ([Figure 3H](#F3){ref-type="fig"}). Rescue of mutant lethality by expressing paxillin only within the pharynx supports our earlier speculation that animals lacking paxillin starve to death. It also leads us to the unexpected conclusion that paxillin is not necessary for the function of body wall muscle in the nematode.

PXL-1 LIM domains are sufficient for proper localization in body wall muscle
----------------------------------------------------------------------------

Previous studies ([@B10]) showed that LIM domains (specifically LIM domain 3) are necessary and sufficient for the localization of paxillin to focal adhesion complexes. To test whether the LIM domains of *pxl-1* are sufficient for proper localization of paxillin in the worm, we constructed a GFP expression construct coding for only the four LIM domains of PXL-1 fused to GFP and under the control of the body wall muscle--specific promoter from the gene T05G5.1 (unpublished data). The extrachromosomal array does not rescue the mutant phenotype, but the GFP-tagged protein containing only LIM domains is localized to dense bodies, adhesion plaques, and M-lines in body wall muscle ([Figure 3F](#F3){ref-type="fig"}). The identical subcellular localization pattern seen with the LIM-only portion of PXL-1 and the full-length PXL-1 indicates that the LIM domains are sufficient for localization of the protein to its proper subcellular locations.

PXL-1 interacts with DEB-1/vinculin, UIG-1, LIM-8, UNC-96, and UNC-95
---------------------------------------------------------------------

LIM-domain proteins, including paxillin, have been implicated as adapter molecules responsible for the recruitment of proteins and acting as a scaffold for protein complexes to assemble ([@B50]; reviewed in [@B11]). We used the yeast two-hybrid method to screen a "bookshelf" of primarily known dense body and M-line proteins using PXL-1a as bait. Six interactors were detected: DEB-1/vinculin, UIG-1, LIM-8, UNC-96, UNC-95, and HUM-6 ([Figure 4A](#F4){ref-type="fig"}). Except for HUM-6 (to be described elsewhere), each positive hit was then retested by fixing HA-tagged PXL-1a to anti-HA beads and incubating with a purified maltose-binding protein (MBP)--tagged sample of each putative interactor. Western blots confirm that each of the putative yeast two-hybrid interactors do bind to PXL-1 in vitro ([Figure 4B](#F4){ref-type="fig"}). Vinculin is a major interactor of paxillin across species (reviewed in [@B11]), and this relationship is conserved in *C. elegans*. Along with DEB-1/vinculin, we also observe in vitro binding between the LD motifs of PXL-1 and the muscle protein LIM-8 and in vitro binding between the LIM domains of PXL-1 and the proteins UIG-1 and UNC-95 ([Figure 4A](#F4){ref-type="fig"}). Two additional proteins, UNC-96 and HUM-6, can bind PXL-1 along the length of the protein. Each of UNC-96 ([@B38]), UIG-1 ([@B23]), and LIM-8 ([@B46]) is expressed in body wall and pharyngeal muscle in vivo. In addition, DEB-1/vinculin is detected in pharyngeal and body wall muscle using the monoclonal antibody (mAb) MH24, and both DEB-1 and UNC-95 have serial analysis of gene expression (SAGE) data indicating expression in those two tissues ([@B36]). Each of the interactions between paxillin and its binding partners can be further expanded by mapping out in vitro interactions between these partners and other proteins found in attachment complexes to show what is likely occurring in vivo ([Figure 6](#F6){ref-type="fig"}). The protein--protein interactions at body wall muscle adhesion junctions have been mapped (reviewed in [@B40]; [@B44]). In pharyngeal muscle, however, the network of interactions is less well studied, as a number of body wall muscle proteins are not found in this tissue, including PAT-3/β-integrin. This means that there is not a one-to-one correspondence between attachment sites between these two types of muscle.

![Body wall muscle in animals with *pxl-1* expression restricted to the pharynx. Animals that were transformed using a *pxl-1a/c::GFP* construct with only ∼150 base pairs of endogenous promoter have *pxl-1* expression almost exclusively in the pharynx. Compared with the body wall muscle structure in wild-type worms observed using polarized light microscopy (A), the muscle structure looks identical in pharyngeal-specific *pxl-1*--rescued animals (B). In animals lacking paxillin in the body wall muscle, actin (antibody C4) is clearly seen (C), whereas GFP antibody does not detect any GFP-tagged paxillin, with only background fluorescence from the secondary antibody observed (D). TEM was also used to look at the body wall muscle structure in wild-type animals (E) and animals lacking *pxl-1* expression in body wall muscle (F), also showing properly formed dense bodies (arrows) and no structural differences. Bars: A--D, 5 μm; E, F, 1 μm.](2551fig5){#F5}

![Protein interactions with PXL-1. PXL-1 is found in dense bodies (A) and M-lines (B), as well as in attachment sites in the pharynx (C). When mapped out, the interactions found in each of these structures can be compared with previously documented interactions. A solid line indicates a confirmed in vitro interaction, and a dotted line indicates that an interaction has only been observed using a yeast two-hybrid method. Proteins highlighted in yellow are found in both dense bodies and M-lines. Proteins found only in dense bodies (green) and those found only in M-lines (red) have also been included. All of the interactions confirmed in this study are labeled with blue lines and confirmed as shown in [Figure 4](#F4){ref-type="fig"}.](2551fig6){#F6}

Comparing protein--protein interactions with genetic interactors of *pxl-1* demonstrates *unc-95* is necessary for *pxl-1* localization in body wall muscle
-----------------------------------------------------------------------------------------------------------------------------------------------------------

To further characterize the interactions we discovered between PXL-1 and four of its binding partners (LIM-8, UIG-1, UNC-95, and UNC-96), we examined PXL-1 localization in body wall and pharyngeal muscle in the mutant background of each interactor. We concentrated our examination on the dense body localization of PXL-1 rather than the M-line localization because of the weak signal for PXL-1::GFP at M-lines. Although PXL-1 is properly localized at dense bodies in *lim-8, uig-1,* and *unc-96* mutant animals, PXL-1 is diffuse in *unc-95* mutants and does not integrate into the dense body structure ([Figure 7](#F7){ref-type="fig"}). The same experiment was carried out testing pharyngeal muscle in the four mutant backgrounds. In *lim-8*, *uig-1*, *unc-95*, and *unc-96* mutant worms, PXL-1 was properly localized to the pharyngeal muscle membrane (unpublished data). Although loss of *unc-95* alters the localization of PXL-1 in body wall muscle, it does not affect its localization in the pharynx.

![Localization of PXL-1 in the mutant background of binding partners. PXL-1 immunostaining was used to observe the subcellular localization of PXL-1 in four mutant backgrounds. A monoclonal antibody for α-actinin was used to label dense bodies. Although PXL-1 is properly localized to dense bodies in the *lim-8*, *uig-1*, and *unc-96* backgrounds, it is diffuse in the cytoplasm in the *unc-95* background. Bar, 10 μm.](2551fig7){#F7}

LIM domain redundancy in body wall muscle?
------------------------------------------

Due to the number of different LIM domain--containing proteins in the worm, it is possible that animals lacking *pxl-1* expression have phenotypically wild-type body wall muscle due to another LIM domain protein compensating for its loss. To test this, we used the strain DM7335, which has *pxl-1* expression in the pharynx but not body wall muscle, and used RNAi feeding to knock down the expression of eight genes coding for LIM domain proteins with known expression in body wall muscle ([@B36]), including *zyx-*1/zyxin and *alp-*1/enigma ([Table 1](#T1){ref-type="table"}). Other than our *pxl-1* RNAi control, each tested gene does not have an RNAi phenotype in wild-type animals, so we screened RNAi-treated DM7335 animals for uncoordinated movement, as well as observed the myofilament organization in muscle cells using polarized light microscopy. Only *lim-8* had any significant effect, with RNAi-treated animals displaying uncoordinated movement and mildly disorganized myofilaments in body wall muscle cells.

###### 

RNAi phenotypes of genes coding for LIM domain proteins in DM7335 animals lacking *pxl-1* body wall muscle expression.

  Gene       RNAi phenotype   Body wall muscle structure
  ---------- ---------------- ----------------------------------
  *pxl-1*    L1 arrest        Wild type
  *zyx-1*    Wild type        Wild type
  *alp-1*    Wild type        Wild type
  *mlp-1*    Wild type        Wild type
  *lim-9*    Wild type        Wild type
  F42H10.3   Wild type        Wild type
  *lim-8*    Uncoordinated    Myofilaments mildly disorganized

Localization of PXL-1--interacting proteins in body wall muscle lacking PXL-1
-----------------------------------------------------------------------------

PXL-1 is localized properly in the mutant background of each of its interactors except for *unc-95* ([Figure 7](#F7){ref-type="fig"}), so we examined the localization of interacting proteins in body wall muscle lacking *pxl-1* expression, using antibodies to stain the strain DM7335 to see whether PXL-1--interacting proteins would be mislocalized ([Figure 8](#F8){ref-type="fig"}). ATN-1/α-actinin is normally localized in a *pxl-1* background and was used to costain animals to mark dense body adhesion complexes ([Figure 8](#F8){ref-type="fig"}). Each of the proteins tested that interact with PXL-1 are normally localized in body wall muscle lacking PXL-1. UNC-95 localization was normal, indicating that in body wall muscle PXL-1 requires UNC-95 for proper localization ([Figure 7](#F7){ref-type="fig"}), but UNC-95 does not require PXL-1. UNC-112/kindlin and DEB-1/vinculin are essential muscle proteins upstream of nonessential muscle proteins (as reviewed in [@B40]) and are normally localized in a *pxl-1* background ([Figure 8](#F8){ref-type="fig"}), as expected. As seen in [Figure 7](#F7){ref-type="fig"}, each of the proteins with which PXL-1 interacts also interacts with multiple other proteins, so PXL-1 may not be solely responsible for their proper localization.

![Localization of PXL-1--interacting proteins in body wall muscle lacking *pxl-1.* Immunostaining for proteins that interact with PXL-1 was carried out using worms that are viable due to *pxl-1* expression in the pharynx but lack body wall muscle expression of *pxl-1*. In body wall muscle lacking PXL-1, each of UNC-95, UNC-96, LIM-8, UIG-1, and UNC-112 is localized normally. UNC-96 is not normally observed in dense bodies with antibody staining in wild-type animals ([@B38]), but in nematodes lacking PXL-1, dense body (arrowheads) and M-line (arrows) localization of UNC-96 is clearly seen in animals stained with anti--UNC-96. Bar, 10 μm.](2551fig8){#F8}

Normally UNC-96 is observed at dense bodies and M-lines using an *unc-96::GFP* translational fusion but only at M-lines using antibody staining ([@B38]). In animals lacking *pxl-1* body wall muscle expression, however, we see M-line and dense body localization using the same UNC-96 antibody. It is possible that PXL-1 may normally sterically block the UNC-96 antibody from binding UNC-96 in dense bodies due to a physical interaction with UNC-96, but in dense bodies lacking PXL-1, the antibody is able to bind UNC-96 with better access to the molecule.

Paxillin is localized around a core of actin filaments in pharyngeal muscle
---------------------------------------------------------------------------

The ring-like localization pattern of paxillin in the pharynx is intriguing because the attachment structures in pharyngeal muscle have previously been assumed to be structurally similar to dense bodies in body wall muscle, albeit with a different complement of proteins. We looked at the distribution of both actin and vinculin in pharyngeal muscle to determine their location relative to paxillin. DEB-1/vinculin colocalizes with PXL-1 in the pharynx in a mix of ring-like and smaller punctate structures ([Figure 9F](#F9){ref-type="fig"}). Because PXL-1 and DEB-1/vinculin are proteins that are in structures that anchor actin, we also looked at the distribution of actin in the pharynx. Antibody staining for actin in animals expressing PXL-1a/c::GFP shows that actin is distributed within the middle of the ring-like structures in pharyngeal muscle, as well as adjacent to the smaller punctate structures containing PXL-1 and DEB-1/vinculin ([Figure 9C](#F9){ref-type="fig"}). Comparison of the actin-anchoring structures in the pharyngeal muscle indicates a structural difference between attachments at the basal membrane and those at the apical (luminal) membrane ([Figure 9, G-H](#F9){ref-type="fig"}). The adhesion complexes at basal membrane have a dome-like shape with actin filaments extending from middle of the structure. Attachment complexes at the luminal membrane are comparatively flatter, with little extension into the cell. Each of these attachment structures differs from those in body wall muscle, which extend from the sarcolemma deep into the cell. The visible structural difference between each attachment and the intriguing pattern of localization for paxillin, vinculin, and actin raise questions about the organization of actin attachment structures found in pharyngeal muscle.

![Actin attachment complexes in pharyngeal muscle. Paxillin is localized to both full and partial ring-like structures in pharyngeal muscle. Full and partial ring-like PXL-1 localization using an anti-GFP antibody (A), along with punctate actin localization (B) using an antiactin antibody. (C) Actin at the middle of the PXL-1 ring-like pattern, with arrows indicating podosome-like attachment structures. The PXL-1 localization in pharyngeal muscle using an anti-GFP antibody (D) is identical to that of DEB-1/vinculin antibody staining (E), as shown in the overlay (F) of their localization patterns. The luminal face of the pharyngeal muscle (G) contains attachment structures (arrows) that differ in size and shape from those found in the cuticular face (H) as shown by TEM. Filaments can be seen projecting into the muscle cell from each type of attachment, as indicated by arrowheads. Membrane invaginations are also visible at the cuticular face of the muscle cell as marked by a star. Bar, 1 μm.](2551fig9){#F9}

DISCUSSION
==========

The *pxl-1* gene in *C. elegans* encodes the orthologue of human paxillin
-------------------------------------------------------------------------

The initial observation that *C. elegans* paxillin has only three strong LD motifs left open the possibility that it is not a true paxillin homologue but rather another member of the paxillin superfamily, more similar perhaps to leupaxin or Hic-5. Leupaxin and Hic-5 are two proteins similar to paxillin, each with four LD motifs, compared with five in paxillin (reviewed in [@B52]). Members of the paxillin superfamily have four LIM domains in the same synteny as paxillin (reviewed in [@B52]), making them possible homologues of *pxl-1*. However, with the possible exception of zebrafish *pxn* ([@B14]), only mammalian proteomes have paxillin and paxillin-related proteins. The third LD motif provides another convincing piece of data in support of PXL-1 being a true paxillin homologue rather than a homologue of the paxillin superfamily. LD motif 3 is not a conventional LD motif in paxillin, as it does not fit the consensus sequence. This sets it apart from all other members of the paxillin superfamily, which have an LD3 motif that strongly matches the consensus sequence ([@B52]). The sequence surrounding LD3 in *Homo sapiens* paxillin aligns strongly with the LD3 sequence in *C. elegans* PXL-1 ([Figure 1C](#F1){ref-type="fig"}), whereas PXL-1 is not similar to the LD3 of other members of the paxillin superfamily. Our protein interaction studies also support the idea that *pxl-1* encodes a paxillin homologue. We found that PXL-1 binds DEB-1 (vinculin), a primary interacting protein of paxillin in adhesion complexes. DEB-1 is expressed in body wall muscle and pharyngeal muscle and is localized to actin attachment complexes ([@B4]).

The gene *unc-95* has also been proposed as a homologue of vertebrate paxillin ([@B9]). UNC-95 is 350 amino acids long and contains one LIM domain near its carboxy terminus ([@B9]). Structurally, PXL-1 has much stronger domain conservation, with all four LIM domains and three of five LD motifs found in vertebrate paxillin. Of note, UNC-95 has an important role in the assembly of body wall muscle ([@B9]), whereas PXL-1 is necessary for the structural integrity of pharyngeal muscle. Both genes are expressed in each muscle tissue, but each appears to be necessary in only one type of muscle. Whether UNC-95 is a weak paxillin homologue with a role in body wall muscle or more similar to another LIM domain--containing protein requires further study.

Finally, it is known that vertebrate paxillin is heavily phosphorylated at tyrosines by Src family kinases ([@B53]); paxillin was originally identified as a phosphoprotein, 65--70 kDa. In the Western blot in [Figure 4D](#F4){ref-type="fig"}, we noticed that nematode PXL-1 has a slower gel mobility than yeast-expressed nematode PXL-1. This would be compatible with PXL-1 being phosphorylated, since *C. elegans* has, but yeast lack, Src family tyrosine kinases. These combined observations lead us to conclude that PXL-1 is a paxillin homologue and is the nematode orthologue of paxillin.

Paxillin is required in the pharynx for muscle function
-------------------------------------------------------

We have found that paxillin is expressed in all body wall and pharyngeal muscle cells in *C. elegans*. Antibody staining and GFP fusion experiments have shown that paxillin is localized to actin attachment structures in each of these muscle types, as well as weakly to the M-line (myosin attachment structure) in body wall muscle. In animals lacking paxillin the pharynx appears to be properly formed, but internally the myofilaments of the pharyngeal sarcomeres are disorganized. This lack of organized sarcomeres is likely what is leading to paralysis and lack of contraction of the pharyngeal muscle and in turn starvation due to an inability to feed ([Figure 3, A--D](#F3){ref-type="fig"}). Expressing *pxl-1* in pharyngeal muscle of *pxl-*1 animals is sufficient to rescue the L1 arrest phenotype, and pharyngeal muscle functions normally. Although the rescued animals display weak expression in the body wall muscle around the anterior tip of the worm, expression is almost fully restricted to the pharyngeal muscle. In body wall muscle cells posterior to the pharynx lacking paxillin, the cells are wild type in structure and movement is not impaired. It is unlikely that weak expression in a small subset of anterior body wall muscle cells is sufficient to rescue a body wall muscle--specific phenotype. Thus we conclude that PXL-1 has an integral role in the contraction of pharyngeal muscle, possibly in transmitting the forces generated by myosin/actin interaction, but no obvious functional role within body wall muscle.

Loss of β-integrin, ILK, UNC-112 or PINCH ([@B17]; [@B24]; [@B49]; [@B32]; [@B42]) each leads to embryonic lethality in *C. elegans*. The diagnostic phenotype of mutations in these genes is a Pat animal (paralyzed and arrested at twofold) ([@B60]). These proteins are all involved in integrin placement and organization of the adhesion complex to accept thick and thin filaments in the initial phase of myofilament formation during development. By contrast, PXL-1 is not required until later in development, as *pxl-1* animals die after embryogenesis and after hatching during the first larval stage. Although the function of paxillin remains to be determined in body wall muscle, it is clearly important for pharyngeal muscle function. This difference in paxillin function in two different muscle tissues is intriguing and may be the result of how myofilaments are organized in body wall muscle versus the pharynx (see later discussion).

Paxillin\'s role in body wall muscle?
-------------------------------------

Although *pxl-1* is expressed in both pharyngeal and body wall muscle, we have found it to be essential only in the pharynx. In the strain DM7335, which lacks *pxl-*1 expression in body wall muscle, the myofilament structure is wild type ([Figure 5](#F5){ref-type="fig"}). It is surprising that *pxl-1* appears to be dispensable in body wall muscle; however, other body wall muscle genes encoding LIM domain proteins lack a mutant or RNAi phenotype, including *zyx-1*/zyxin ([@B51]) and *alp-1* ([@B21]), which encodes homologues for both α-actinin--associated LIM protein and the LIM protein enigma ([@B35]). The lack of a mutant or RNAi phenotype for these genes raises the question of whether there is redundancy, or genetic buffering, where more than one of these LIM domain proteins would need to be lost to elicit a phenotype. In our RNAi screen of genes encoding LIM domain proteins carried out using strain DM7335 that lacks *pxl-1* expression in body wall muscle ([Table 1](#T1){ref-type="table"}), *lim-8* knockdown resulted in uncoordinated movement and mild disorganization of the myofilaments. In a wild-type background, RNAi for *lim-8* does not have such an effect ([@B46]). Although *pxl-1* does not have a clear role in body wall muscle and its loss does not cause any visual changes to the tissue, our observations with *lim-8* indicate that muscle lacking *pxl-1* is not as robust as wild-type muscle when exposed to additional gene loss.

Muscle attachment structures in *C. elegans* pharyngeal muscle are structurally similar to podosomes
----------------------------------------------------------------------------------------------------

The actin-anchoring dense bodies in the worm have attracted interest from researchers studying focal adhesion complexes due to the similarity in protein composition between these two dynamic structures. Less well studied are the attachment structures of the nematode pharynx, which we propose resemble podosomes. In podosomes, actin filaments form the core of the attachment complex and are surrounded by a ring of proteins found in focal adhesion proteins such as vinculin, paxillin, and integrin heterodimers (reviewed in [@B58]). Whereas the dense body structures in *C. elegans* body wall muscle appear punctate when observed using a fluorescent marker for paxillin, the attachment structures in the pharynx appear ring-like, which is what we would expect to see with a podosome-like structure. In EM images, the body wall muscle dense body ([Figure 5, D--F](#F5){ref-type="fig"}) and pharyngeal attachment complex ([Figure 9, G--H](#F9){ref-type="fig"}) appear as dense structures at their respective membranes. Membrane invaginations are also present at the cuticular face of the pharyngeal muscle as well; however they do not appear to be associated with the sarcomere itself ([Figure 9H](#F9){ref-type="fig"}). The assumption has been that the attachment structure in pharyngeal muscle is similar to the dense body in body wall muscle, with actin filaments attaching outward from a core of attachment proteins, rather than actin forming a core on which attachment proteins form a ring-like structure to anchor it. Here we provide the first data that indicate otherwise.

PXL-1a/c::GFP localization in the pharynx is in ring-like structures within the muscle cell membranes, as well as in comparatively smaller punctate structures. Actin staining reveals that actin is localized within the middle of the paxillin-containing rings, as well as directly adjacent to paxillin punctae ([Figure 9C](#F9){ref-type="fig"}). This raises an interesting question as to how ring-like adhesion structures are formed in pharyngeal muscle. It is possible that the initial accumulation of paxillin in the membrane leads to actin recruitment and attachment and subsequent encircling of the actin core by paxillin and other attachment proteins. In [Figure 9C](#F9){ref-type="fig"}, both partial and full paxillin-containing rings can be seen, each encircling concentrated actin. Determining the exact mechanism of building a podosome-like structure will require future experimentation.

Defining the pharyngeal muscle attachment structure as podosome-like is supported by the expression and localization of a number of other podosome-associated proteins. DEB-1 (vinculin) colocalizes with PXL-1 in the pharyngeal muscle membrane in a ring-like pattern ([Figure 9F](#F9){ref-type="fig"}). INA-1 (α-integrin), and ATN-1 (α-actinin) are expressed in pharyngeal muscle ([@B25]; [@B6]), but their exact localization pattern has not been established. Surprisingly, PAT-3 (β-integrin) is not expressed in developing and mature pharyngeal muscle. It is possible that there is another β-integrin in the *C. elegans* genome; however, a suitable candidate has not yet been identified. Whereas a null mutant for DEB-1 arrests embryonically and has paralyzed body wall muscle, the pharyngeal muscle is not completely paralyzed in all animals ([@B5]). In contrast, the pharyngeal muscle in *pxl-1* null mutants is paralyzed, whereas the body wall muscle appears unaffected. The requirement of paxillin in the pharyngeal muscle for proper sarcomere organization and muscle contraction indicates that paxillin is a key component of the pharyngeal sarcomere. Further investigation into the requirement and localization of proteins found within pharyngeal muscle will lead, it is hoped, to a more complete understanding of the structure and function of the sarcomere in the pharynx.

MATERIALS AND METHODS
=====================

Strains
-------

N2 (Bristol) is the principal wild-type strain used in *C. elegans* research and was grown using standard conditions ([@B8]). The VC1012 (*tag-327*(*ok1483*)/*mT1*\[*dpy-10*(*e128*)\] III) strain was provided by the International *C. elegans* Gene Knockout Consortium (Vancouver, Canada). The *ok1483* mutation is a 943--base pair deletion in the *pxl-1* gene, and animals homozygous for *ok1483* arrest development as L1 larvae. Balancing of the homozygous lethal genotype was accomplished by crossing in the chromosome III balancer *mT1*, a *dpy-10* marked translocation. Strain GE24 (*pha-1*(*e2123*ts) III) was used for one microinjection because of its temperature-sensitive lethal phenotype ([@B18]). Animals homozygous for *pha-1*(*e2123*ts) arrest development during embryogenesis at 25C but are viable at 15C. Adult animals grown at 15C can be injected with DNA encoding a wild-type *pha-1* gene and then transferred to 25C. Only progeny harboring the injected DNA as an extrachromosomal array survive. Strain NJ0784 (N2; rhIs1\[*pat-3*::GFP; pRf4(*rol-6*)\]) produces GFP-tagged PAT-3 and was used to confirm colocalization of PXL-1 with PAT-3 in body wall muscle.

Production of *ok1483-*rescuing GFP translational fusions
---------------------------------------------------------

Construction of a GFP translational fusion able to rescue animals homozygous for the *ok1483* allele was accomplished by using PCR to amplify the full sequence of C28H8.6b along with ∼2.4 kb of endogenous promoter region to clone into the pPD95.75 GFP expression vector provided by Andrew Fire (Stanford University). Similarly, the coding sequence of C28H8.6a along with ∼150 base pairs of its endogenous promoter was amplified and cloned into pPD95.75. Primers were designed to eliminate the stop codon in C28H8.6b and C28H8.6a while also allowing for it to be inserted into pPD95.75 such that it would be in-frame with GFP sequence downstream of the multiple cloning site. The 3′ untranslated region for *unc-54* is downstream of the coding sequence for GFP in the pPD95.75 vector.

Construction of a Gateway GFP translational fusion
--------------------------------------------------

A GFP translational fusion for the LIM domain--coding portion of *pxl-1* was produced by taking advantage of the ORFeome ([@B47]) publicly available from Open Biosystems (Thermo Biosystems, Huntsville, AL). The *C. elegans* ORFeome consists of 12,625 open reading frames (ORFs) cloned into a Gateway ([@B57]) donor vector (Invitrogen, Carlsbad, CA). On the basis of methodology described in Meissner *et al*. (2011), a GFP-tagged "'LIM domain--only" paxillin construct was created, driven by the body wall muscle--specific promoter T05G5.1.

Identification of *pxl-1* splice isoforms
-----------------------------------------

Forward primers specific to the exons in the 5′ portion of the previously named C28H8.13 gene were used to attempt to amplify RT-PCR products using each of the two 3′ exons of C28H8.6. Three splice isoforms were confirmed by sequencing the isolated cDNAs and named C28H8.6a, C28H8.6b, and C28H8.6c, with GenBank accession numbers EU239658, EU239659, and EU239660, respectively. Our analysis demonstrates that C28H8.13 and C28H8.6 are one gene, now termed C28H8.6 or *pxl-1*. Our analysis of the alternative splicing of *pxl-1* is also supported by data from whole-genome transcriptional tiling array experiments ([@B22]).

Isolation of a full-length *pxl-1a* cDNA
----------------------------------------

Primers flanking the 5′ and 3′ exons of *pxl-1a* were used to amplify the *pxl-1a* cDNA using RT-PCR. The forward primer contained a 5′ *Hin*dIII restriction site, and the reverse primer contained a 3′ *Eco*RV site to allow for cloning into the pBlueScript SK-plasmid vector. The cloned cDNA was sequenced to confirm identical sequence to the annotated National Center for Biotechnology Information sequence.

Microinjection procedure
------------------------

Transformation of worms with GFP translational fusion constructs was carried out using microinjection. Two coinjection markers were used in this process: pRF4 \[*rol-6*(*su1006dm*)\], which contains a copy of *rol-6* and results in a Rol phenotype of successful transformants, and pBx \[*pha-1*::*pha-1*(+)\], which is able to rescue the embryonic lethal *pha-1* phenotype of the strain GE24. Injection mixes were prepared containing either 45 ng/μl pRF4, 45 ng/μl pBx, and 10 ng/μl of GFP-tagged construct for injection into GE24 animals or 90 ng/μl pRF4 *rol-6*(*su1006dm*) and 10 ng/μl GFP-tagged construct for injection into animals heterozygous for the *ok1483* null allele of *pxl-1* and phenotypically balanced with the recessive mutation *dpy-17*. All injections were carried out using a microinjection setup featuring a Zeiss inverted compound microscope (IM35) by conventional methods ([@B37]). The four transgenic strains obtained were DM7055 (*pha-1*­(*e2123*) III; *raEx55*\[*pha-1*(+); *rol-6*(*su1006*); pT05G5.1::C28H8.­6a::GFP\]), DM7082 (*tag-327*(*ok1483*) III; *raEx82*\[*rol-6*(*su1006*); C28H8.6b::GFP\]), DM7335 (*tag-327*(*ok1483*) III; *raEx335*\[*rol-6*(*su1006*); C28H8.6a/c::GFP\]), and DM7438 (*tag-327*(*ok1483*) III; *raEx438*\[*rol-6*(*su1006*); pC28H8.6::C28H8.6a(cDNA)::GFP\])

RNAi feeding
------------

RNAi feeding clones from the frozen Geneservice feeding library (Source BioScience LifeSciences, Nottingham, United Kingdom) were picked and grown overnight in Luria (L) broth containing 50 μg/ml ampicillin. Specialized nematode growth medium plates were prepared containing 1 mM isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside to induce production of dsRNA in bacteria and 50 μg/ml carbenicillin to select for bacteria containing an RNAi construct. These plates were then streaked with 50 μl of overnight culture and incubated at room temperature overnight to allow for dsRNA production. Approximately 20 L1 worms were spotted onto each RNAi plate by transferring a small aliquot of the previously prepared M9 solution containing the hatched animals. These plates were then incubated at 20ºC until the worms reached the young adult stage (∼60--68 h). Four worms from each plate were then transferred to fresh RNAi plates corresponding to the same feeding construct (two plates, each with two worms) and left for ∼18 h to lay embryos, at which time they were removed. The phenotype of affected worms was assayed over the next 2 d.

Antibody production
-------------------

An MBP fusion of the PXL-1a N-terminus (residues 1--112) was used as immunogen for preparation of anti--PXL-1 antibodies. The cDNA fragment was cloned into pMAL-KK-1. BL21 (DE3) CodonPlus bacteria (Stratagene, Santa Clara, CA) was used for production of MBP-PXL-1 (residues 1--112), which was supplied to Spring Valley Laboratories (Woodbine, MD) for production of rabbit antibodies. After affinity purification using a column containing MBP-PXL-1 (residues 1--112), antibodies were evaluated by reaction to a Western blot containing a lysate of soluble *C. elegans* proteins and a lysate from yeast expressing HA-tagged PXL-1 full-length cDNA. A yeast expression plasmid for HA-tagged PXL-1 full-length (residues 1--413) was constructed by two-step cloning: first, the cDNA of PXL-1 full-length was cloned into pKA-HA(Nhex2); second, the *Nhe*I fragment containing HA-tagged PXL-1 full-length (residues 1--413) was cloned into pGAP-C-Nhe ([@B30]; [@B42]). The PJ69-4A yeast strain harboring pGAP-C-HA-PXL-1 plasmid was cultured in 2 ml of media until saturation, and the cells were collected. Yeast lysate was prepared by suspending yeast cells in Laemmli buffer, heating at 95°C for 5 min. The Western blot was performed as described previously ([@B38]).

Yeast two-hybrid method
-----------------------

Yeast two-hybrid assays were performed as described previously ([@B32]). The PCR-amplified cDNA fragments of PXL-1a full-length (residues 1--413), PXL-1a N-terminus (residues 1--112), and PXL-1a LIM domains (residues 113--413) tagged with *Bam*HI and *Sal*I were cloned into pGBDU-C1 (bait) and pGAD-C1 (prey) yeast two-hybrid vectors ([@B26]). Yeast host strain PJ69-4A harboring a combination of PXL-1 bait and "bookshelf" collection ([@B46]) preys or PXL-1 prey and "bookshelf" collection bait plasmids was examined for HIS3 and ADE2 reporters on selective plates.

HA-pulldown assay
-----------------

Bacterial expression plasmids for MBP fusions of UNC-95 full-length, UNC-96 C-terminal half (residues 201--411), and LIM-8 (residues 635--1004) were described previously ([@B38]; [@B46]). Bacterial expression plasmids for the MBP fusion of DEB-1 (residues 1--291) and UIG-1 (residues 1--638) were made by cloning each cDNA fragment a into pMAL vector. MBP and other MBP fusions were expressed in *Escherichia coli* and purified as described previously ([@B38]). On the basis of a yeast lysate containing HA-tagged PXL-1 full-length (residues 1--413) and purified MBP or MBP fusion proteins, a HA-pulldown assay was carried out as described previously ([@B45]).

Immunostaining
--------------

For the images shown in [Figures 7](#F7){ref-type="fig"} and [8](#F8){ref-type="fig"}, worms were fixed by the Nonet method ([@B41]). Antibody staining with anti--PXL-1 (1:100 dilution) and anti--α-actinin (MH35, 1:200 dilution) was performed as described previously ([@B46]). Secondary antibodies were anti--rabbit Alexa 488 (Invitrogen) for anti--PXL-1 and anti--mouse Alexa 594 (Invitrogen) for anti--α-actinin, each used at 1:200 dilution. Stained samples were mounted on a glass slide with a coverslip containing mounting solution (20 mM Tris, pH 8.0, 0.2 M 1,4-diazabicyclo\[2.2.2\]octane \[DABCO\], and 90% glycerol). Images were captured with a Zeiss confocal system (LSM510) equipped with an Axiovert 100M microscope using an Apochromat 63×/1.4 oil objective in 2.5× zoom mode. The color balances of the images were adjusted by using Adobe Photoshop (San Jose, CA). All additional antibody staining was carried out using a method modified from [@B1]. Worms were washed off plates and suspended in 4% sucrose, 1 mM EDTA, pH 7.4, solution. Some animals were dissected to expose the pharynx for images in [Figure 9](#F9){ref-type="fig"}. The worm suspensions were transferred to glass slides coated with 2 mg/ml poly-[l]{.smallcaps}-lysine, covered by a rectangular glass coverslip, and frozen on an aluminum slab at −80°C overnight. The coverslips were removed from the slides using a razor blade, and slides were transferred to −20°C methanol for 4 min, −20°C acetone for 4 min, and subsequent 1-min intervals of 75% acetone at 20°C, 50% acetone, 25% acetone, and Tween/Tris-buffered saline (TBS) for 2 min. Primary antibodies solutions were added to the slides for 5 h, and included anti--PXL-1 (1:100 dilution), antiactin (AbCam8224) at 1:500 dilution, antivinculin (MH24; [@B16]) at 1:250 dilution, and anti-GFP (AbCam13970) at 1:1000 dilution. After 1 h in TBS/Tween, slides were coated with secondary antibodies for 3 h, Alexa 488 (Invitrogen) for anti--PXL-1, Alexa 594 for antiactin and antivinculin, and Dylight 488 (703485155; Jackson ImmunoResearch, West Grove, PA) for anti-GFP. After 1 h in TBS/Tween, mounting solution was added (20 mM Tris, pH 8.0, 0.2 M DABCO, and 90% glycerol), and slides were sealed with nail polish.

Microscopic analysis
--------------------

All phenotypic analysis of worms homozygous for the mutant allele *ok1483* or affected by RNAi targeting C28H8.6 was carried out using a dissecting microscope (Wild Heerbrugg model) and a fluorescence dissecting microscope (Stemi SV11; Zeiss, Thornwood, NY). Whole-worm images and immunofluorescence images were taken using a Zeiss Axiophot compound microscope with a QImaging QICAM digital camera running Qcapture, version 1.68.4, and a Zeiss Axioplan 2 imaging compound microscope with 2.5× Optivar and a QImaging Retiga EXi digital camera. Images in [Figure 4C](#F4){ref-type="fig"} were obtained using a Zeiss Axiovert inverted compound microscope with a Zeiss Pascal confocal setup (LSM5) using Pascal imaging software, version 3.2sp2. Fluorescence images in [Figure 9](#F9){ref-type="fig"} were processed with Image J software (National Institutes of Health, Bethesda, MD), using the Parallel Iterative Deconvolution 2D plug-in (version 1.11).

TEM microscopy
--------------

Worms were removed from growth media and immersed in fixative (1.5% paraformaldehyde, 1.5% glutaraldehyde, 0.1 M sodium cacodylate, pH 7.3, room temperature). Under a microscope, the anterior halves of the animals were removed and collected in a small vial. After fixing for ∼3 h, the fixative was replaced with buffer (0.1 M sodium cacodylate, pH 7.3) and the samples left at room temperature until the following day. Samples were washed twice with buffer, postfixed (1% OsO~4~ in 0.1 M sodium cacodylate) for 1 h on ice, washed three times with dH~2~O, en bloc stained for 1 h with 1% uranyl acetate (aqueous), and then washed again three times with dH~2~O. Samples were dehydrated through a graded series of ethanol and then infiltrated through propylene oxide into EMbed 812 (Electron Microscopy Sciences, Hatfield, PA). The worm halves were oriented in the embedding molds so that the midsection of the worm and the pharynx could be transversely cut when sectioned, and then the resin hardened at 60°C overnight. Thin sections were stained with uranyl acetate and lead citrate and photographed on a Philips 300 operated at 60 kV.
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